Navigation Links
ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

IRVINE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today reported financial results for the three months ended September 30, 2009. ISTA reported net revenue of $32.0 million for the three months ended September 30, 2009, a 47% increase over net revenue for the three months ended September 30, 2008. Included in the net revenue for the three months ended September 30, 2009 is $1.2 million associated with the launch of Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% and $2.9 million of previously deferred revenue associated with the termination of a supply agreement. In addition, ISTA reported operating income of $5.2 million and positive cash flow of $8.2 million in the quarter, as the Company progresses towards reporting its first operating income breakeven year.

"In September, we received FDA approval to begin marketing Bepreve, a new treatment for ocular itching associated with allergic conjunctivitis. We immediately launched Bepreve, by making the decision to add over 60 new sales territories and shipping samples of Bepreve to key customers within days of the product's approval. I am pleased to report we have been receiving strong positive feedback from physicians using Bepreve in their practices," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA. "Our sales force is excited, and we are very proud of what we have accomplished so far, but we have just begun. The ocular allergy market is the largest market we have entered to date, and Xibrom and Istalol continue to show strong growth. We believe ISTA will finish 2009 in a strong position to allow us to continue building upon our commercial success next year.

"With respect to our product candidates under development, we reported positive preliminary Phase 3 results from our Xibrom 0.0
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... This market report summarizes the ... carried out in May 2013. The full report ... the responses for each question, its segmentation and ... highlights some interesting differences, particularly between Pharma, Biotech ... were developed to estimate the in house and ...
(Date:5/24/2013)... Toronto, Canada (PRWEB) May 24, 2013 ... selective barriers, and uptake or efflux transporters at the ... may be related to unbound fractions in the tissue ... understanding of these disposition challenges is required to guide ... and to identify any species-dependent variables that may impact ...
(Date:5/24/2013)... May 24, 2013 The Oklahoma tornado ... following its ravage, the mayor of Moore, one of the ... houses, said a report from cnn.com. Reaching out to also ... complimentary Molderizer and Safe Shield to counter the looming mold ... published on May 22, 2013, caused 24 deaths, My Cleaning ...
(Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...
Breaking Biology Technology:Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5
... adept at climbing through difficult terrain using an intricate adhesive ... how they switch on their unique system of traction. ... South Carolina have discovered that the geckos, amazing grip is ... adhesive research will be published Wed., Aug. 5, at 00:001 ...
... , , SOUTH SAN ... PARD ), a biopharmaceutical company focused on oncology, today reported financial ... a corporate update. , , "During the ... 2 picoplatin data from our colorectal and prostate cancer programs. ...
... NEW YORK, Aug. 4 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... 8:30 a.m. EDT to discuss the second quarter 2009 financial results and ... Officer of the Company, will host the call. Keryx will announce ... issued prior to the call. , , In order ...
Cached Biology Technology:New angle on gecko research 2Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update 8Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT 2
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery reveals ... , Within the genome of each species, there ... change in position and sequence over millions of years, ... these evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), ... or the condensation of chromosomes, but the function of ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than ... of intellectual property at PNNL,s annual Intellectual Property ... The Department of Energy national laboratory named materials ... his work developing battery materials that can store ... electrical grid, and reduce the time it takes ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... at the University of Georgia have developed a "super ... pretreated pine -- one of the most common species ... could help biofuels replace gasoline as a transportation fuel. ... biomass such as pine, but it is a notoriously ...
... of small rodents throwing themselves off the top of cliffs ... longer be determined by hearsay as a new report suggests ... climate. The study, published today, 18 November, in IOP ... may be maintaining the biomass of certain plants in the ...
... The Seventh Annual Symposium on Predictive Health, to be ... health and the human microbiome. The human microbiome consists ... viruses, which reside throughout the body. Study of ... across the United States, including a major federal initiative ...
Cached Biology News:UGA researchers develop 'super' yeast that turns pine into ethanol 2Could lemmings be involved in regulating our climate? 2Predictive health symposium will focus on human microbiome 2
... The Xcise is a powerful technology ... throughput proteome analysis. High quality sample ... untrained user. , The Xcise is a ... for high throughput proteome analysis. It combines ...
Extra Large bottle for hybridization 300 x 70mm...
Request Info...
... Thermo IEC Microtube Rotor is TWO ROTORS ... change rotors. You can spin both ... tubes. Exclusive polypropylene rotor design provides excellent ... Polypropylene rotors are fully compatible with ...
Biology Products: